[Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia]
Pei-Fang Xiao1, Shao-Yan Hu1, Hai-Long He1
1Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, Jiangsu Province, China.
Insights
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is effective for children with severe aplastic anemia (SAA). Donor lymphocyte infusions can improve engraftment, making allo-HSCT a viable first-line treatment option.
Area of Science:
- Hematology
- Pediatric Oncology
- Immunology
Context:
- Severe aplastic anemia (SAA) is a life-threatening condition in children.
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potential cure.
- Limited data exists on various donor sources for pediatric SAA allo-HSCT.
Purpose:
- To evaluate the efficacy of allo-HSCT in children with SAA.
- To assess outcomes using HLA-matched sibling, umbilical cord blood, and haploidentical donors.
- To determine the role of donor lymphocyte infusions (DLI) in managing graft failure.
Summary:
- Eleven children with SAA underwent allo-HSCT using HLA-matched siblings, cord blood, or haploidentical donors.
- Engraftment was achieved in 10 patients; 3 experienced secondary graft failure, successfully treated with DLI.
- One patient had primary graft rejection after cord blood transplant but achieved autologous recovery. Median neutrophil and platelet recovery times were documented.
Impact:
- Allo-HSCT is a recommended first-line treatment for pediatric SAA when an HLA-matched sibling donor is available.
- Umbilical cord blood and haploidentical HSCT are feasible alternative donor sources for pediatric SAA.
- Donor lymphocyte infusions are effective in improving engraftment in cases of graft failure.
Objective:
To study the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with severe aplastic anemia (SAA).
Methods:
A total of 11 children with SAA were treated with HLA matched siblings (n = 7), umbilical cord blood (n = 2) and haploidentical HSCT (n = 2).
Results:
Among 11 children patients, 10 patients achieved engraftment, but 3 children patients experienced secondary graft failure, after donor lymphocyte infusions (DLI), they achieved engraftment again. One patient received cord blood transplantation and experienced primary graft rejection, but acquired autologous recovery. The median time for neutrophils to reach over 0.5 × 10(9)/L was 14 days (10-19 days) in the 9 children received bone marrow or bone marrow and peripheral blood allo-HSCT, while the median time for platelets to reach over 20 × 10(9)/L was 17 days (8-42 days). For the patient received double cord blood transplantation, the time of neutrophile and platelet level recovery was 16 days and 41 days, respectively.
Conclusion:
If HLA-matched sibling donor is available, allo-HSCT can be recommended as the first line of treatment for children with SAA. It is feasible for children with SAA to receive allo-HSCT from selective donor, including cord blood and haploidentical HSCT. Donor lymphocyte infusions can improve engraftment.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:01Regulation of Hematopoietic Stem Cells